Department of Acupuncture and Tuina, Changchun University of Chinese Medicine, Changchun, Jilin, China.
Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, Jilin, China.
PLoS One. 2024 Jan 17;19(1):e0296749. doi: 10.1371/journal.pone.0296749. eCollection 2024.
Type 2 diabetes mellitus (T2DM) is a chronic and progressive condition defined by hyperglycemia caused by abnormalities in insulin production, insulin receptor sensitivity, or both. Several studies have revealed that higher body mass index (BMI) is associated with increasing risk of developing diabetes. In this study, we perform a protocol for systematic review to explore metabolite biomarkers that could be used to identify T2DM in obese subjects.
The protocol of this review was registered in PROSPERO (CRD42023405518). Three databases, EMBASE, PubMed, and Web of Science were selected to collect potential literature from their inceptions to July December 2023. Data for collection will include title, authors, study subjects, publication date, sample size, detection and analytical platforms, participant characteristics, biological samples, confounding factors, methods of statistical analysis, the frequency and directions of changes in potential metabolic biomarkers, and major findings. Pathway analysis of differential metabolites will be performed with MetaboAnalyst 5.0 based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) and the Human Metabolome Database.
The results of this systematic review will be published in a peer-reviewed journal.
This systematic review will summarize the potential biomarkers and metabolic pathways to provide a new reference for the prevention and treatment of T2DM in obese subjects.
2 型糖尿病（T2DM）是一种由胰岛素产生异常、胰岛素受体敏感性异常或两者共同导致的高血糖所定义的慢性进行性疾病。多项研究表明，较高的体重指数（BMI）与患糖尿病的风险增加相关。在这项研究中，我们制定了一项系统评价方案，以探索可用于识别肥胖人群中 T2DM 的代谢物生物标志物。
本综述的方案已在 PROSPERO（CRD42023405518）中注册。从数据库的建立到 2023 年 7 月至 12 月，我们选择了 EMBASE、PubMed 和 Web of Science 三个数据库来收集潜在的文献。收集的数据将包括标题、作者、研究对象、出版日期、样本量、检测和分析平台、参与者特征、生物样本、混杂因素、统计分析方法、潜在代谢标志物变化的频率和方向，以及主要发现。基于京都基因与基因组百科全书（KEGG）和人类代谢组数据库（HMDB），将使用 MetaboAnalyst 5.0 对差异代谢物进行途径分析。
本系统评价的结果将发表在同行评议的期刊上。
本系统评价将总结潜在的生物标志物和代谢途径，为肥胖人群 T2DM 的预防和治疗提供新的参考。
